EMVision Medical Devices Ltd (ASX:EMV)

Australia · Delayed Price · Currency is AUD

1.770

+0.010 (0.57%)

Apr 29, 2026, 4:10 PM AEST

-9.69% (1Y)

Market Cap	163.57M
Revenue (ttm)	5.43M
Net Income (ttm)	-10.20M
Shares Out	92.94M
EPS (ttm)	-0.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,595
Average Volume	60,334
Open	1.700
Previous Close	1.760
Day's Range	1.680 - 1.770
52-Week Range	1.480 - 2.430
Beta	1.01
RSI	54.23
Earnings Date	May 22, 2026

About EMVision Medical Devices

EMVision Medical Devices Ltd engages in the research, development, and commercialization of neurodiagnostic technology for stroke diagnosis and monitoring, and other medical imaging needs in Australia. It offers non-invasive brain scanners, including emu Brain Scanner, a bedside device; and First Responder Brain Scanner, a device embedded in standard road and air ambulances to deliver pre-hospital stroke diagnosis and care to patients. The company was incorporated in 2017 and is based in Macquarie Park, Australia. [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2017

Country Australia

Stock Exchange Australian Securities Exchange

Ticker Symbol EMV

Full Company Profile

Financial Performance

In fiscal year 2025, EMVision Medical Devices's revenue was 5.05 million, a decrease of -54.97% compared to the previous year's 11.22 million. Losses were -9.81 million, 259.2% more than in 2024.

Financial Statements

News

EMVision Medical Devices Transcript: NWR Virtual Healthcare Conference

A novel portable brain scanner using radio frequency signals is advancing stroke and brain injury care, with strong clinical data, major partnerships, and a robust patent portfolio. Market entry is focused on hospitals and ambulances, with pivotal trials supporting regulatory submissions.

5 weeks ago - Transcripts

EMVision Medical Devices Transcript: Life Sciences Virtual Investor Forum

Portable brain scanners for stroke and traumatic brain injury are nearing pivotal trial completion, with strong clinical data and a U.S. launch targeted for 2027. The company is leveraging industry partnerships, robust IP, and a scalable business model to address large global markets.

6 weeks ago - Transcripts

EMVision Medical Devices Transcript: Investor Update

Transitioning to commercialization, two neurodiagnostic devices are advancing through pivotal clinical trials and regulatory pathways, targeting major U.S. and international markets. Strategic partnerships, robust funding, and a phased launch plan underpin growth, with multiple clinical and regulatory milestones ahead.

8 months ago - Transcripts